Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.40 |
| ▸ | MAPT | P10636 | 8/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.40 |
| ▸ | MEN1 | O00255 | 5/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3997753 | 0.78 | MEN1 (0.37) | ALDH1A1MAPTKMT2AMEN1TDP1 | |
| SCHEMBL3248203 | 0.75 | ALDH1A1 (0.43) | ALDH1A1MAPTKMT2AMEN1CYP1A2 | |
| SCHEMBL28007162 | 0.68 | MAPT (0.54) | ALDH1A1MAPTKMT2AMEN1CYP1A2 | |
| SCHEMBL11339444 | 0.68 | ALDH1A1 (0.47) | ALDH1A1MAPTKMT2AMEN1CYP1A2 | |
| SCHEMBL4000308 | 0.66 | SMN1; SMN2 (0.46) | ALDH1A1KMT2AMEN1SMN1; SMN2PKM | |
| SCHEMBL17225381 | 0.65 | MAPT (0.50) | ALDH1A1MAPTKMT2AMEN1CYP1A2 | |
| SCHEMBL844567 | 0.65 | — | — | |
| SCHEMBL16397013 | 0.64 | STAT3 (0.42) | ALDH1A1SMN1; SMN2NTRK1 | |
| SCHEMBL6392481 | 0.62 | PARP1 (0.49) | ALDH1A1KMT2AMEN1CYP1A2CYP3A4 | |
| SCHEMBL11631291 | 0.62 | ALDH1A1 (0.63) | ALDH1A1MAPTKMT2AMEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7462614-B2 | Imidazotriazine compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-09 | — | — | US | disclosed |
| US-20060217382-A1 | 7-(2-Bromophenyl)-5-methyl-N-(3,4,5-trimethoxyphenyl)imidazo[5,1-f][1,2,4]triazin-2-amine; to treat neoplasms; polo like kinases inhibitors; antineoplastic/antiproliferative agents; cyclization of 1,2,4-triazine derivatives; coupling if imidazo[5,1-f][1,2,4]triazines with amine or halogen derivatives | SMITHKLINE BEECHAM CORPORATION | 2006-09-28 | — | — | US | disclosed |
| EP-1608656-A2 | IMIDAZOTRIAZINE COMPOUNDS | SmithKline Beecham Corporation (US) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004087652-A2 | IMIDAZOTRIAZINE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217382-A1 | 7-(2-Bromophenyl)-5-methyl-N-(3,4,5-trimethoxyphenyl)imidazo[5,1-f][1,2,4]triazin-2-amine; to treat neoplasms; polo like kinases inhibitors; antineoplastic/antiproliferative agents; cyclization of 1,2,4-triazine derivatives; coupling if imidazo[5,1-f][1,2,4]triazines with amine or halogen derivatives | PLK2, PLK1, CDKL5 | ALDH1A1 3450/4885MAPT 2687/4885KMT2A 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.